Fig. 1From: Coding joint: kappa-deleting recombination excision circle ratio and B cell activating factor level: predicting juvenile dermatomyositis rituximab response, a proof-of-concept studyStudy hypothesis illustration. JDM subjects with significant oligoclonal B cell expansion will have a good response to Rituximab if they achieved complete B cell depletion evident by bone marrow B cell reconstitution (Image was created by the authors)Back to article page